LC-MS raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-03-30. Anything still debated is marked as such rather than presented as settled.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ in preclinical models |
| Molecular formula | C20H24ClN3O4S | Reported for the parent compound |
| CAS Registry Number | 1379686-30-2 | Common identifier in chemical databases |
| Appearance | Off-white to pale yellow solid | Typical research chemical solid |
| Solubility | Soluble in DMSO and ethanol; low in water | Class: small organic molecule |
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
=== Cancer === In cancer, tumours take over the body's vascularisation processes to supply themselves with blood, helping them grow and spread. Anti-angiogenic therapies are currently used in combination with other therapies for cancer management. Bevacizumab, a monoclonal antibody & VEGF inhibitor is approved for use in cancer treatment.
== Management of ships == Fleet management also refers to the management of ships while at sea. Shipping fleet management contracts are normally given to fleet management companies that handle aspects like crewing, maintenance, and day-to-day operations. This gives the ship owner time to concentrate on cargo booking.
=== Notable people === The American pop singer Michael Jackson had the condition, which he obscured with costumes and makeup until it covered his body. This led to some inaccurate speculation that he had bleached his skin. Other notable cases include the American rapper Krizz Kaliko, the Canadian fashion model Winnie Harlow, the New Zealand singer-songwriter Kimbra, the American actor David Dastmalchian, the Argentine musician Charly García, the professional wrestler Bryan Danielson, the French actor Michaël Youn, the former French Prime Minister Édouard Philippe, Miss Universe Egypt 2024 Logina Salah, governor of Pampanga Eddie Panlilio, and the Colombian model Taliana Vargas.
=== Ethnopharmacological Perspectives === The Journal of Ethnopharmacology provides extensive documentation of insect based treatments in indigenous medicine. Ethnopharmacological research has revealed that insects are integral to traditional healing systems in many cultures. In South America ant and wasp venoms are used in pain management and inflammation control. Also in India scorpions and centipedes have been incorporated into Ayurvedic medicine for treating neurological disorders. These case studies illustrate the cultural diversity in insect based medicine and underscore the potential for modern pharmacological applications.
Sources: en.wikipedia.org
In February 2020, Marguerite Stern, alongside Christine Delphy and Fatiha Agag-Boudjahlat, co-signed a column written by Pauline Arrighi entitled "Trans: suffit-il de s'autoproclamer femme pour pouvoir exiger d'être considéré comme telle?" ("Trans: is it enough to proclaim oneself a woman to be able to demand to be considered as such"). This column was initially published in HuffPost and later taken town the editorial staff, who described it as transphobic. It was later republished by Marianne. On February 26, 2020, several personalities and associations signed two columns in Libération entitled "Féminisme: le débat sur la place des femmes trans n'a pas lieu d'être" ("Feminism: the debate on the place of trans women has no place") and "À toi ma sœur, mon frère, mon adelphe" ("To you my sister, my brother, my sibling"). These opposed pieces crystallized the ongoing dissension within the collage movement over transgender rights. Marguerite Stern was harassed for her positions, and received death threats, which led to psychiatric hospitalization for generalized anxiety disorder. In September 2021, seven authors responded to these views by withdrawing from a feminist book fair due to Stern and fellow activist Dora Moutot's participation. In August 2022, she co-signed with Dora Moutot a column published in Marianne addressed to Élisabeth Borne, in which they opposed a Planned Parenthood poster with a pregnant transgender man, stating that "it uses vocabulary used by transactivists".
Folin's reagent or sodium 1,2-naphthoquinone-4-sulfonate is a chemical reagent used as a derivatizing agent to measure levels of amines and amino acids. The reagent reacts with them in alkaline solution to produce a fluorescent material that can be easily detected.
The Venezuelan government remained in place, with Rodríguez sworn in as acting president on 5 January 2026. Multiple political prisoners (including foreigners) detained in Venezuela were released, a gesture which, according to Trump, contributed to avoiding a second wave of attacks. On 30 January, Rodríguez announced an amnesty bill for political prisoners covering the period of 1999 to present, which was approved on 19 February. As of 8 March, the number of political prisoners released confirmed since 8 January was 621 out of an estimate of over 800 held before January, according to human rights organizations. By February, the US and Venezuela had restarted diplomatic relations, with the Embassy of the United States, Caracas, being reopened for the first time since 2019. According to The New York Times, Venezuela has been a de facto puppet state since the intervention, with the US State Department under Marco Rubio exercising control over core aspects of Venezuela's governance, including its domestic finances, government appointments, revenues, foreign policy, and the distribution of its natural resources. Trump and his administration made clear that access to Venezuelan oil was a core reason for the action. The US announced a 50-million-barrel oil supply deal with the remaining government in Venezuela, with the first $300 million already received on 20 January. On 29 January, a new law was passed by Rodríguez to give private companies control over the production and sale of oil.
Sources: en.wikipedia.org
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.
No. It is a synthetic ligand that binds nuclear receptors, not a steroid or peptide hormone. Its activity depends on receptor binding rather than endocrine secretion.
Clinical evidence is limited. Most published data come from cell and animal experiments. Human safety and efficacy remain uncertain.
Its legal status depends on the country and intended use. It is not an approved medicine in major jurisdictions. In sport, it is prohibited by anti-doping rules.